FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387664554> ?p ?o ?g. }

• W4387664554 abstract "The oncogenic transcription factors STAT3, STAT5A and STAT5B are essential to steer hematopoiesis and immunity, but their enhanced expression and activation drives the development or progression of blood cancers. Current therapeutic strategies focus on blocking upstream tyrosine kinases, but frequently occurring resistance often leads to disease relapse, emphasizing the need for more targeted therapies. Here we evaluate JPX-0700 and JPX-0750, which are STAT3/5-specific covalent cysteine binders that lead to growth arrest of acute myeloid leukemia (AML) and natural killer/T cell lymphoma (NKCL) cell lines in vitro and in vivo, as well as reduce cell viability of primary AML blasts ex vivo. Our non-PROTAC small molecular weight degraders selectively reduce STAT3/5 activation and total protein levels, as well as downstream target oncogene expression, exhibiting nanomolar to low micromolar efficacy. We found that both AML and NKCL cells hijack STAT3/5 signaling through either upstream activating mutations in tyrosine kinases, activating gain-of-function mutations in STAT3, mutational loss of negative STAT regulators, or genetic gains in anti-apoptotic, pro-proliferative or epigenetic-modifying STAT3/5 targets. Moreover, we have shown synergistic inhibitory action of JPX-0700 and JPX-0750 upon combinatorial use with approved chemotherapeutics (doxorubicin, daunorubicin, cytarabine), epigenetic enzyme blocker vorinostat, tyrosine kinase inhibitor cabozantinib or BCL-2 inhibitor venetoclax. Importantly, JPX-0700 or JPX-0750 treatment reduced leukemic cell growth in human AML/NKCL xenograft mouse models without adverse side effects. These potent small molecule degraders of STAT3/5 could propel further clinical development for use in AML and NKCL patients." @default.
• W4387664554 created "2023-10-17" @default.
• W4387664554 creator A5006306448 @default.
• W4387664554 creator A5006466935 @default.
• W4387664554 creator A5007387735 @default.
• W4387664554 creator A5008868111 @default.
• W4387664554 creator A5008966909 @default.
• W4387664554 creator A5012933847 @default.
• W4387664554 creator A5014678514 @default.
• W4387664554 creator A5016681267 @default.
• W4387664554 creator A5017634740 @default.
• W4387664554 creator A5023390854 @default.
• W4387664554 creator A5026664404 @default.
• W4387664554 creator A5027654274 @default.
• W4387664554 creator A5032243711 @default.
• W4387664554 creator A5037938281 @default.
• W4387664554 creator A5043819864 @default.
• W4387664554 creator A5043913136 @default.
• W4387664554 creator A5044559524 @default.
• W4387664554 creator A5048087410 @default.
• W4387664554 creator A5055510016 @default.
• W4387664554 creator A5061588223 @default.
• W4387664554 creator A5070170202 @default.
• W4387664554 creator A5071321419 @default.
• W4387664554 creator A5072136925 @default.
• W4387664554 creator A5072949561 @default.
• W4387664554 creator A5075978656 @default.
• W4387664554 creator A5078130097 @default.
• W4387664554 creator A5078395212 @default.
• W4387664554 creator A5080915549 @default.
• W4387664554 creator A5090966690 @default.
• W4387664554 date "2023-10-16" @default.
• W4387664554 modified "2023-10-17" @default.
• W4387664554 title "Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma" @default.
• W4387664554 doi "https://doi.org/10.1101/2023.10.12.561697" @default.
• W4387664554 hasPublicationYear "2023" @default.
• W4387664554 type Work @default.
• W4387664554 citedByCount "0" @default.
• W4387664554 crossrefType "posted-content" @default.
• W4387664554 hasAuthorship W4387664554A5006306448 @default.
• W4387664554 hasAuthorship W4387664554A5006466935 @default.
• W4387664554 hasAuthorship W4387664554A5007387735 @default.
• W4387664554 hasAuthorship W4387664554A5008868111 @default.
• W4387664554 hasAuthorship W4387664554A5008966909 @default.
• W4387664554 hasAuthorship W4387664554A5012933847 @default.
• W4387664554 hasAuthorship W4387664554A5014678514 @default.
• W4387664554 hasAuthorship W4387664554A5016681267 @default.
• W4387664554 hasAuthorship W4387664554A5017634740 @default.
• W4387664554 hasAuthorship W4387664554A5023390854 @default.
• W4387664554 hasAuthorship W4387664554A5026664404 @default.
• W4387664554 hasAuthorship W4387664554A5027654274 @default.
• W4387664554 hasAuthorship W4387664554A5032243711 @default.
• W4387664554 hasAuthorship W4387664554A5037938281 @default.
• W4387664554 hasAuthorship W4387664554A5043819864 @default.
• W4387664554 hasAuthorship W4387664554A5043913136 @default.
• W4387664554 hasAuthorship W4387664554A5044559524 @default.
• W4387664554 hasAuthorship W4387664554A5048087410 @default.
• W4387664554 hasAuthorship W4387664554A5055510016 @default.
• W4387664554 hasAuthorship W4387664554A5061588223 @default.
• W4387664554 hasAuthorship W4387664554A5070170202 @default.
• W4387664554 hasAuthorship W4387664554A5071321419 @default.
• W4387664554 hasAuthorship W4387664554A5072136925 @default.
• W4387664554 hasAuthorship W4387664554A5072949561 @default.
• W4387664554 hasAuthorship W4387664554A5075978656 @default.
• W4387664554 hasAuthorship W4387664554A5078130097 @default.
• W4387664554 hasAuthorship W4387664554A5078395212 @default.
• W4387664554 hasAuthorship W4387664554A5080915549 @default.
• W4387664554 hasAuthorship W4387664554A5090966690 @default.
• W4387664554 hasBestOaLocation W43876645541 @default.
• W4387664554 hasConcept C203014093 @default.
• W4387664554 hasConcept C2778041864 @default.
• W4387664554 hasConcept C2778461978 @default.
• W4387664554 hasConcept C2778729363 @default.
• W4387664554 hasConcept C2779282312 @default.
• W4387664554 hasConcept C42362537 @default.
• W4387664554 hasConcept C502942594 @default.
• W4387664554 hasConcept C62478195 @default.
• W4387664554 hasConcept C86803240 @default.
• W4387664554 hasConcept C95444343 @default.
• W4387664554 hasConceptScore W4387664554C203014093 @default.
• W4387664554 hasConceptScore W4387664554C2778041864 @default.
• W4387664554 hasConceptScore W4387664554C2778461978 @default.
• W4387664554 hasConceptScore W4387664554C2778729363 @default.
• W4387664554 hasConceptScore W4387664554C2779282312 @default.
• W4387664554 hasConceptScore W4387664554C42362537 @default.
• W4387664554 hasConceptScore W4387664554C502942594 @default.
• W4387664554 hasConceptScore W4387664554C62478195 @default.
• W4387664554 hasConceptScore W4387664554C86803240 @default.
• W4387664554 hasConceptScore W4387664554C95444343 @default.
• W4387664554 hasLocation W43876645541 @default.
• W4387664554 hasOpenAccess W4387664554 @default.
• W4387664554 hasPrimaryLocation W43876645541 @default.
• W4387664554 hasRelatedWork W1980883331 @default.
• W4387664554 hasRelatedWork W1993422021 @default.
• W4387664554 hasRelatedWork W2269392306 @default.
• W4387664554 hasRelatedWork W2357037178 @default.
• W4387664554 hasRelatedWork W2364732766 @default.
• W4387664554 hasRelatedWork W2781637722 @default.
• W4387664554 hasRelatedWork W2969404813 @default.
• W4387664554 hasRelatedWork W2990397977 @default.

• next